Skip to main content
. 2017 Feb 12;10(1):24. doi: 10.3390/ph10010024

Figure 4.

Figure 4

Tumour volumes, survival rates and CK2 activity and expression in CX-4945 treated mice. Tumour volumes (recorded at days 5, 11 and 16 p.i.) of treated (n = 6, black line) and control non-treated bearing tumour mice (n = 6, red line) for (A) CX-4945 treated every day GL261 implanted mice and (B) CX-4945 treated alternated days GL261 implanted mice. No significant differences were observed between groups (p > 0.05). The dashed blue line indicates the CX-4945 therapy start point; (C) Survival Kaplan-Meier curve for CX-4945 treated every day mice (n = 6) and control mice (n = 6); (D) Survival Kaplan-Meier curve for CX-4945 treated alternated days mice (n = 6) and control mice (n = 6). No significant differences were found between groups (p > 0.05). The dashed blue line indicates the CX-4945 therapy start point; (E) Tumour CK2 activity (%) in mice treated with CX-4945, n = 3, compared with control mice, n = 3. (* = p < 0.05 for Student’s t-test for the comparison of control and treated groups); (F) Western blot for tumour total protein homogenate (40 µg) from different mice treated with CX-4945, n = 3, compared with control mice, n = 3. p-Akt(S129), Akt1 total, CK2α, and α-tubulin proteins were analyzed; (G) Quantification of Western blot for tumour total protein homogenate (40 µg) from mice treated with CX-4945, n = 3, compared with control mice, n = 3. Ratio (%) of p-Akt (S129) content divided by Akt1 total content. * = p < 0.05 for Student’s t-test for the comparison of control and treated groups.